| Revenue growth | Pharmacy operations revenue grew 23.4% YoY on reported basis. |
|---|---|
| Margins | Pharmacy EBITDA at 5.6%; mature stores stable at 13.1%. |
| Demand visibility | Strong visibility driven by omni-channel presence and pharmacy demand. |
| Management confidence | Balanced; optimistic on franchise model, defensive regarding store closures. |
Growth
Revenue grew 23.4% YoY in pharmacy operations; mature stores (>12 months) maintain 13.1% EBITDA margins.
Outlook
Targeting 800 net new stores in FY27, including significant franchise participation to drive profitability.
Risks
Rising store closures (77 in Q4) and high inventory days (112) for new stores remain concerns.
Earnings Call filed with NSE, NSE: MEDPLUS. Summary written with AI assistance from the document.
Medplus Health Services Ltd: key numbers
- Share price
- ₹654.90
- Market cap
- ₹7,868 Cr
- Revenue (annual)
- ₹6,892 Cr
- Net profit (annual)
- ₹219.7 Cr
- P/E (TTM)
- 37.4×Sector 57.8×
- Promoter holding
- 40.19%-0.03% QoQ
- FII holding
- 14.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medplus Health Services Ltd
All →Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary, Optival Health Solutions, faced a three-day drug license suspension at a store by the Drugs Control Administration, impacting operations by ₹0.01 Crore.
- Value
- ₹0.01 Cr
- From
- Drugs Control Administration, Haveri Circle, Karnataka
Medplus Health Services Legal & Regulatory
MedPlus Health Services' subsidiary, Optival Health Solutions, received a one-day drug license suspension from the Drugs Control Administration for a store in Telangana due to non-compliance.
- Value
- ₹0.01 Cr
Medplus Health Services Legal & Regulatory
Medplus Health Services' subsidiary, Optival Health, received a 7-day drug license suspension in Andhra Pradesh and stay orders for previous suspensions in Maharashtra.
- Value
- ₹0.02 Cr
Medplus Health Services Legal & Regulatory
Medplus Health Services disclosed that regulatory authorities suspended the drug licenses of five subsidiary stores for 3 to 7 days. The expected financial impact is ₹0.10 Crore.
- Value
- ₹0.10 Cr
Medplus Health Services Adverse Business Impact
Medplus Health Services reported a 7-day drug license suspension for a subsidiary store, impacting its operations with an estimated financial loss of ₹0.02 Crore.
- Value
- ₹0.02 Cr
- Execution
- 7 days
Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary, Optival Health Solutions, faced drug license suspensions for two stores from regulatory authorities, causing a total financial impact of Rs 0.0961 Crore.
- Value
- ₹0.10 Cr
- Execution
- 5 to 15 days